<DOC>
	<DOC>NCT00150228</DOC>
	<brief_summary>The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019</brief_summary>
	<brief_title>12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>Subjects must have smoked an average of at least ten cigarettes per day during the past year No period of abstinence greater than three months in the past year Subjects with history of clinically significant cardiovascular disease Subjects with uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>